Physician profile
James M Jacobs
NPI 1033114822
$80,786.48
in general payments reported to CMS, 2019-2025
37 companies · $1,778 in 2025
The $1,778 reported for 2025 was more than what 92% of Foot Surgery providers received nationally (typical 2025 total: $180).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $25K · 2021: $270 · 2022: $616 · 2023: $746 · 2024: $550 · 2025: $1,778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,750 · Food and Beverage: $1,218 · Travel and Lodging: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,750.00 |
| Food and Beverage | $1,218.03 |
| Travel and Lodging | $105.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fuse Medical, INC. | $77,262.81 | 2019-2025 | Orbitum Staple System, Orbitum Staple System |
| Stryker Corporation | $492.15 | 2019-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit, Augment Injectable |
| Sandoz INC. | $462.26 | 2019-2020 | |
| Sanara Medtech INC. | $289.11 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $271.16 | 2019-2023 | Jublia |
| Boston Scientific Corporation | $219.56 | 2022-2025 | Watchman Flx |
| Voom Medical Devices, INC. | $202.88 | 2025 | Revcon Instrument Kit, Sterile, Revcon |
| Abbvie INC. | $169.20 | 2022 | |
| Smith+Nephew, INC. | $156.71 | 2019-2025 | Renasys Touch, Regranex, Collagenase Santyl |
| Lifenet Health | $153.90 | 2025 | Theragenesis Wound Matrix |
| Orthofix Medical, INC. | $113.33 | 2019-2022 | |
| Averitas Pharma INC. | $98.47 | 2024 | Qutenza |
| Alafair Biosciences, INC. | $81.23 | 2024-2025 | Versawrap |
| Zyla Life Sciences, INC. | $76.49 | 2019-2020 | |
| Cpm Medical Consultants, LLC | $74.79 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $65.91 | 2021-2022 | |
| Bioventus LLC | $64.17 | 2019-2025 | Exogen Ultrasound Bone Healing System, Exogen Ultrasound Bone Healing System |
| Amgen INC. | $55.84 | 2024-2025 | Krystexxa |
| Melinta Therapeutics, LLC | $52.71 | 2019-2020 | |
| Treace Medical Concepts, INC. | $46.81 | 2025 | |
| Ani Pharmaceuticals, INC. | $46.56 | 2025 | Purified Cortrophin Gel |
| Zimmer Biomet Holdings, INC. | $40.58 | 2019 | |
| Nevro Corp. | $33.24 | 2022 | |
| Paratek Pharmaceuticals, INC. | $31.54 | 2025 | Nuzyra |
| Mayne Pharma Commercial LLC | $29.40 | 2021 | |
| Anika Therapeutics, INC. | $28.05 | 2021 | |
| Abbott Laboratories | $21.25 | 2024 | Proclaim |
| Fidia Pharma USA INC. | $19.16 | 2025 | |
| Horizon Therapeutics Plc | $18.56 | 2023 | Krystexxa |
| Triad Life Sciences INC. | $18.21 | 2022 | |
| Nabriva Therapeutics, Plc | $17.13 | 2020 | |
| Kci USA, INC. | $15.29 | 2021 | |
| Medtronic Vascular, INC. | $15.16 | 2020 | |
| Heron Therapeutics, INC. | $14.45 | 2023 | Zynrelef |
| Medimetriks Pharmaceuticals, INC. | $14.40 | 2020 | |
| Sebela Pharmaceuticals INC. | $14.01 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$34,975.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.